A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
Crossref DOI link: https://doi.org/10.1007/s00280-016-3198-0
Published Online: 2016-12-03
Published Print: 2017-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Doi, Toshihiko
Fuse, Nozomu
Yoshino, Takayuki
Kojima, Takashi
Bando, Hideaki
Miyamoto, Hideaki
Kaneko, Masato
Osada, Motonobu
Ohtsu, Atsushi
Funding for this research was provided by:
Bayer Yakuhin Ltd (N/A)
License valid from 2016-12-03